ReviewWorld journal of surgical oncology2026
Primary pulmonary osteosarcoma: a case report, literature review and pooled analysis.
Review in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary pulmonary osteosarcoma (PPOS) is an exceptionally rare malignant tumor that arises within the lung parenchyma. Fewer than 40 cases of PPOS have been reported to date. Owing to its rarity, the clinical features and prognostic factors of PPOS remain poorly defined.
objectiveTo report a new case of PPOS and perform a pooled retrospective analysis of published cases to identify clinical profiles and potential prognostic determinants.
methodsA comprehensive literature review was conducted using the PubMed, Medline, and Cochrane Library databases. Thirty-eight reported cases of PPOS were identified. Among these, sufficient clinical and survival data of 25 patients, including one from our institution, were available for analysis. Overall survival (OS) was assessed using the Kaplan-Meier method and Cox proportional hazards models.
resultsThe median age of the pooled cohort was 64 years. Kaplan-Meier and multivariable Cox analyses demonstrated that older age (> 64 years) was associated with poorer OS and that surgical resection significantly improved survival. Among surgical patients, adjuvant chemotherapy was associated with a trend toward prolonged OS, although the difference was not statistically significant (P = 0.053). Age-stratified analysis revealed a survival benefit of surgery in both the ≤ 64-year age group and the > 64-year age group (P = 0.003 and P < 0.001, respectively), and no significant difference in OS was observed according to tumor size among surgically treated patients (P = 0.89).
conclusionPPOS is an aggressive malignancy with poor prognosis. Age and surgical resection were found to be crucial prognostic factors. A combination of surgery and chemotherapy may offer additional survival benefits to selected patients. Given that the benefits of surgery were observed across all age groups and that no difference in survival was observed according to tumor size among surgically treated patients, advanced age and larger tumor size alone should not preclude consideration of surgical intervention in patients with adequate performance status. Larger multi-institutional studies are needed to validate these findings.
Indexed as
Identifiers
42881466What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.